Market access outlook: 2027 trends in an unpredictable climate

From United States policy developments and European health policy changes to Most Favored Nation pricing, artificial intelligence, real-world evidence, and direct-to-consumer models, the report offers practical perspectives for navigating uncertainty with greater confidence. 

What you will learn

• How evolving United States coverage, affordability, and formulary dynamics may increase the need for manufacturer support programs. 
• Why interconnected European policies and Joint Clinical Assessment requirements demand earlier, cross-functional planning. 
• How scenario planning can help organizations assess potential global pricing and launch-sequencing implications of Most Favored Nation policies. 
• Where artificial intelligence can support evidence generation and decision-making, while maintaining transparency and human judgment. 
• Why real-world evidence is becoming essential to demonstrate value for regulators, payers, and patients. 
• How direct-to-consumer models are evolving in response to coverage gaps and influencing payer engagement. 

Organizations that build evidence differently, stay informed, connect decisions across functions, and keep patient needs central will be better positioned to respond to change.